Upstream Bio Inc

Research Upstream Bio Inc (UPB) on Bullrun: market cap USD 377.13M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerUPB
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 377.13M
• Financial periodFY2025
• RevenueUSD 2.85M
• Revenue growth20.4%
• Net income-USD 143.44M
• Free cash flow-USD 133.44M

Valuation Snapshot

latest market cap is USD 377.13M.

About Upstream Bio Inc

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

What is Upstream Bio Inc's market cap?

Upstream Bio Inc's market capitalization is USD 377.13M.

What does Upstream Bio Inc do?

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.